Veröffentlichungen
Abivax’s lead drug candidate, obefazimod (originally known as ABX464), is an investigational drug candidate that has not yet been approved for commercial use in any jurisdiction, but it has already garnered plenty of attention in the industry. The following collection of publications can offer a more complete understanding of the potential of obefazimod.
2023
-
Obefazimod: a first-in-class drug for the treatment of ulcerative colitis ulcerosa
J Crohns Colitis.2023;17(10):1689-1697. -
ABX464 (obefazimod) upregulates miR124 to reduce proinflammatory markers in inflammatory bowel diseases
Clin Transl Gastroenterol.2023;14(4):e00560.
2022
-
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension 2b und eine 48-wöchige, offene Verlängerungsstudie
Lancet Gastroenterol Hepatol.2022;7(11):1024-1035. -
Safety and efficacy of the miR-124 upregulator ABX464 (obefazimod, 50 and 100 mg per day) in patients with active rheumatoid arthritis and inadequate response to methotrexate and/or anti-TNFα therapy: a placebo-controlled phase II study 100 mg pro Tag) bei Patienten mit aktiver rheumatoider Arthritis und unzureichendem Ansprechen auf Methotrexat und/oder Anti-TNFα-Therapie: eine placebokontrollierte Phase-II-Studie
Ann Rheum Dis.2022;81(8):1076-1084.
2021
-
Induction and long-term follow-up with ABX464 for moderate-to-severe ulcerative colitis: results of phase IIa trial
Gastroenterology.2021;160(7):2595-2598.e3. -
Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases Chinolin ABX464: eine transformative Therapie für entzündliche Erkrankungen
Drug Discov Today.2021;26(4):1030-1039.
2019
-
Both anti-inflammatory and antiviral properties of novel drug candidate ABX464 are mediated by modulation of RNA splicing Wirkstoffkandidaten ABX464 werden durch Modulation des RNA-Spleißens vermittelt.
Sci Rep.2019;9(1):792.
2017
-
The anti-Hiv candidate Abx464 dampens intestinal inflammation by triggering Il-22 production in activated macrophages
Sci Rep.2017;7(1):4860. -
Pharmacokinetics and tolerability of ABX464, a novel first-in-class compound to treat HIV infection, in healthy HIV-uninfected subjects
J Antimicrob Chemother.2017;72(3):820-828.
2016
-
Randomized trial of food effect on pharmacokinetic parameters of ABX464 administered orally to healthy male subjects
Antimicrob Agents Chemother.2016;61(1):e012288-16.
2015